InvestmentTop NewsUncategorized

Regional hub: Why Merck picked Cote d’Ivoire


Nation’s economic competitiveness continues to thrill foreign investors


By Ada Anioji


In a classic case of putting the horse before the cart, the pharmaceutical conglomerate, Merck, has stated that its choice of Cote d’Ivoire for the location of its regional hub in West Africa is because that nation is about the most competitive business destination in the region at the moment.

According to a statement from the firm, the affiliate office in Côte d’Ivoire will serve as regional hub for Merck’s operations in French speaking countries in Central and West Africa.

A leading German science and technology company, Merck has also donated 2 minilabs to Côte d’Ivoire supporting their fight against counterfeit medicines.

“For several years, Côte d’Ivoire has shown continuous growth, as well as economic, political and social stability. The main driver of this achievement being its increase in competitiveness and steady progress in economic development,” Dr. Frank Stangenberg-Haverkamp, Chairman of the Executive Board and the Family Board of E. Merck KG, said at the opening. “We are excited to open this office in Abidjan, which will be our first in Francophone Sub-Saharan Africa.”

The office was inaugurated by his Excellency, the Ambassador of the Federal Republic of Germany to Côte d’Ivoire, Dr. Claus Auer and key representatives of the Ivorian government along with Dr. Stangenberg-Haverkamp and Dr. Karim Bendhaou, President of North & West Africa.

“This new office will allow us to reinforce and to develop our already existing activities in the country and it will be the hub for French speaking countries in Central and West Africa. We will continue to bring specialist and high-quality products to serve patients and help them to improve their quality of life,” added Dr. Bendhaou.

Merck also donated two minilabs with the aim of supporting Côte d’Ivoire in its fight against counterfeit medicines. The minilabs, which help to detect counterfeits, are manufactured by the Global Pharma Health Fund (GPHF), a charitable initiative financed by Merck.

“We are pleased that our plan to establish a public-private partnership to combat counterfeits will be translated into effective measures with the donated minilabs, in addition to an awareness campaign led by the Minister of Health and Public Hygiene,” Bendhaou said. The donation ceremony was graced by The First Lady of Côte d’Ivoire, Dominique Claudine Ouattara and H.E. Minister of Health and Public Hygiene, Dr. Raymonde Goudou Coffie. These minilabs will be the first to be used in Côte d’Ivoire.

“This donation done by Merck will allow us to reinforce our structures for drug monitoring. The people will be reassured that they are investing in medicines which are safe, not dangerous and suitable for consumption,” H.E. Minister of Health and Public Hygiene expressed her gratitude for this donation. “The mobile compact laboratories are globally renowned for their ability to detect counterfeits quickly, cost-efficiently and reliably. The Ministry of Health and Public Hygiene makes quality control its top priority.”

Merck’s fight against counterfeit medicines is part of the company’s health-related corporate responsibility initiatives. Many people in low- to middle-income countries lack access to high-quality health solutions and Merck is leveraging its expertise and collaborating with strong partners to develop innovative solutions for such patients.



Cote d’Ivoire President, Alasane Quattara



Gordhan fights back, exposes the Guptas

Previous article

Guptagate: Malema backs Gordhan

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

More in Investment